241 
HR 2862 PP 
made by subparagraph (A) to meet the needs re-
sulting from natural disasters. 
(C) REPORT.—Not later than 12 months 
after the date on which the Secretary of Agri-
culture 
issues 
guidelines 
under 
paragraph 
(3)(A), and annually thereafter, the Secretary 
shall submit to the Committee on Small Business 
and Entrepreneurship and the Committee on Ag-
riculture, Nutrition, and Forestry of the Senate 
and to the Committee on Small Business and the 
Committee on Agriculture of the House of Rep-
resentatives, a report that— 
(i) describes the effectiveness of the as-
sistance made available under section 
321(a) of the Consolidated Farm and Rural 
Development Act (7 U.S.C. 1961(a)), as 
amended by this section; and 
(ii) 
contains 
recommendations 
for 
ways to improve the assistance provided 
under such section 321(a). 
(D) EFFECTIVE
DATE.—The amendments 
made by this paragraph shall apply during the 
4-year period beginning on the earlier of the date 
on which guidelines are published by the Sec-
retary of Agriculture under paragraph (3), or 30
242 
HR 2862 PP 
days after the date of enactment of this Act, with 
respect to assistance under section 321(a) of the 
Consolidated Farm and Rural Development Act 
(7 U.S.C. 1961(a)), as amended by this para-
graph. 
(3) GUIDELINES AND RULEMAKING.— 
(A) GUIDELINES.—Not later than 30 days 
after the date of enactment of this Act, the Ad-
ministrator of the Small Business Administra-
tion and the Secretary of Agriculture shall each 
issue guidelines to carry out paragraphs (1) and 
(2), respectively, and the amendments made 
thereby, which guidelines shall become effective 
on the date of their issuance. 
(B) RULEMAKING.—Not later than 30 days 
after the date of enactment of this Act, the Ad-
ministrator of the Small Business Administra-
tion, after consultation with the Secretary of En-
ergy, shall promulgate regulations specifying the 
method for determining a significant increase in 
the 
price 
of 
kerosene 
under 
section 
7(b)(5)(A)(iii)(II) of the Small Business Act, as 
added by this Act. 
(l) 
BUDGETARY
TREATMENT
OF
LOANS
AND 
FINANCINGS.—
243 
HR 2862 PP 
(1) IN
GENERAL.—Assistance made available 
under any loan made or approved by the Administra-
tion under this section, subsections (a) or (b) of sec-
tion 7 of the Small Business Act (15 U.S.C. 636(a)), 
as amended by this section, except for subsection 
7(a)(23)(C), or financings made under title V of the 
Small Business Investment Act of 1958 (15 U.S.C. 
695 et seq.), as amended by this section, on and after 
the date of enactment of this Act, shall be treated as 
separate programs of the Small Business Administra-
tion for purposes of the Federal Credit Reform Act of 
1990 only. 
(2) USE OF FUNDS.—Assistance under this sec-
tion and the amendments made by this section shall 
be available effective only to the extent that funds are 
made available under appropriations Acts, which 
funds shall be utilized to offset the cost (as such term 
is defined in section 502 of the Federal Credit Reform 
Act of 1990) of such assistance. 
(m) EMERGENCY SPENDING.—Appropriations under 
this section are designated as emergency spending, as pro-
vided under section 402 of H. Con. Res. 95 (109th Con-
gress). 
ANTIDEFICIENCY ACT 
SEC. 530. EXTENSION OF UNIVERSAL SERVICE FUND 
EXEMPTION FROM THE ANTIDEFICIENCY ACT.
244 
HR 2862 PP 
Section 302 of the Universal Service Antideficiency 
Temporary Suspension Act is amended by striking ‘‘Decem-
ber 31, 2005,’’ each place it appears and inserting ‘‘Decem-
ber 31, 2006,’’. 
SMALL BUSINESS FEES 
SEC. 531. SMALL BUSINESS FEES. 
(a) FEES.—Section 7(a)(23) of the Small Business Act 
(15 U.S.C. 636(a)(23)) is amended by striking subpara-
graph (C) and inserting the following: 
‘‘(C) LOWERING OF FEES.— 
‘‘(i) IN GENERAL.—Subject to clauses 
(ii) and (iii)— 
‘‘(I) the Administrator may re-
duce fees paid by small business bor-
rowers and lenders under clauses (i) 
through (iv) of paragraph (18)(A) and 
subparagraph (A) of this paragraph; 
and 
‘‘(II) fees paid by small business 
borrowers and lenders shall not be in-
creased above the levels in effect on the 
date of enactment of the Consolidated 
Appropriations Act, 2005. 
‘‘(ii) DETERMINATIONS.—A reduction 
in fees under clause (i) shall occur in any 
case in which the fees paid by all small
245 
HR 2862 PP 
business borrowers and by lenders for guar-
antees under this subsection, or the sum of 
such fees plus any amount appropriated to 
carry out this subsection, as applicable, is 
more than the amount necessary to equal 
the cost to the Administration of making 
such guarantees.’’ 
SEC. 532. None of the funds made available in this 
Act may be used to include in any new bilateral or multi-
lateral trade agreement the text of— 
(1) paragraph 2 of article 16.7 of the United 
States-Singapore Free Trade Agreement; 
(2) paragraph 4 of article 17.9 of the United 
States-Australia Free Trade Agreement; or 
(3) paragraph 4 of article 15.9 of the United 
States-Morocco Free Trade Agreement. 
TITLE VI—RESCISSIONS 
DEPARTMENT OF JUSTICE 
GENERAL ADMINISTRATION 
COUNTERTERRORISM FUND 
(RESCISSION) 
Of the unobligated balances available under this head-
ing, $11,000,000 are rescinded.
246 
HR 2862 PP 
LEGAL ACTIVITIES 
ASSETS FORFEITURE FUND 
(RESCISSION) 
Of the unobligated balances available under this head-
ing, $82,000,000 are rescinded. 
FEDERAL BUREAU OF INVESTIGATION 
SALARIES AND EXPENSES 
(RESCISSION) 
Of the unobligated balances available under this head-
ing, $103,502,000 are rescinded; of which $30,000,000 shall 
be from funding for J. Edgar Hoover Federal Bureau of 
Investigation Building tours; and of which $73,502,000 
shall be from funding for the Federal Bureau of Investiga-
tion’s failed computer modernization program. 
TITLE VII— 
METHAMPHETAMINES 
SECTION 701. SHORT TITLE. 
This title may be cited as the ‘‘Combat Meth Act of 
2005’’. 
Subtitle A—Amendments to 
Controlled Substances Act 
SEC. 710. PSEUDOEPHEDRINE AND EPHEDRINE AMEND-
MENTS TO CONTROLLED SUBSTANCES ACT. 
(a) ADDITION OF PSEUDOEPHEDRINE AND EPHED-
RINE TO SCHEDULE V.—The matter under schedule V in
247 
HR 2862 PP 
section 202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)) is amended by adding at the end the following: 
‘‘(6) Any detectable quantity of pseudoephedrine 
or ephedrine, their salts or optical isomers, or salts of 
optical isomers.’’. 
(b) PRESCRIPTIONS.—Section 309(c) of the Controlled 
Substances Act (21 U.S.C. 829(c)) is amended— 
(1) by striking ‘‘No controlled substance’’ and in-
serting the following: 
‘‘(1) IN
GENERAL.—No controlled substance’’; 
and 
(2) by adding at the end the following: 
‘‘(2) RETAIL DISTRIBUTORS AND PHARMACIES.— 
If a controlled substance described in paragraph (6) 
of schedule V is dispensed or sold at retail by a retail 
distributor or a pharmacy, the retail distributor or 
pharmacy shall ensure the following: 
‘‘(A) QUALIFICATIONS OF DISPENSER.—The 
substance shall be dispensed or sold at retail only 
by practitioner, pharmacist, or an individual 
under the supervision of a pharmacist as per-
mitted by the State. 
‘‘(B) REQUIREMENTS
FOR
PURCHASER.— 
Any person purchasing, receiving, or otherwise
248 
HR 2862 PP 
acquiring any such substance shall, prior to tak-
ing possession— 
‘‘(i) provide an approved Federal or 
State-issued photo identification or an al-
ternative form of identification authorized 
by the Attorney General; and 
‘‘(ii) sign or make an entry in a writ-
ten or electronic log that conforms with the 
regulations under paragraph (4) docu-
menting— 
‘‘(I) the date of the transaction; 
‘‘(II) the name of the person; and 
‘‘(III) the name and the amount 
of the controlled substance described in 
paragraph (6) of schedule V purchased, 
received, or otherwise acquired. 
‘‘(C) LIMITATION
ON
AMOUNT
OF
PUR-
CHASE.—No person shall purchase, receive, or 
otherwise acquire more than 7.5 grams of a con-
trolled substance described in paragraph (6) of 
schedule V within any 30-day period. 
‘‘(3) EXEMPTIONS.— 
‘‘(A) IN GENERAL.—The Attorney General, 
by rule, may exempt a product from paragraph 
(6) of schedule V if the Attorney General deter-
249 
HR 2862 PP 
mines that the product cannot be used in the ille-
gal manufacture of methamphetamine or any 
other controlled dangerous substance. 
‘‘(B) DIFFERENT FORMULATION.— 
‘‘(i) IN GENERAL.—The Attorney Gen-
eral, upon the application of a manufac-
turer of a drug product, may exempt a 
product from paragraph (6) of schedule V if 
the Attorney General determines that the 
product has been formulated in such a way 
as to effectively prevent the conversion of the 
active ingredient into methamphetamine. 
‘‘(ii) SENSE OF CONGRESS.—It is the 
sense of Congress that the Secretary of 
Health and Human Services should con-
sider a product under clause (i) to be sub-
ject to the performance goals established by 
the Commissioner of Food and Drugs for 
priority drugs. 
‘‘(C) SPECIAL EXCEPTIONS.—The Attorney 
General, by rule, may authorize the sale of a 
controlled substance described in paragraph (6) 
of schedule V by persons other than a practi-
tioner, and at a location other than a pharmacy 
if—
250 
HR 2862 PP 
‘‘(i) the Attorney General— 
‘‘(I) determines that the retail fa-
cility is located within a commercial 
service airport, and sells the substance 
packaged in liquid and liquid filled 
gelcaps only, each single sales package 
containing not more than 360 mg, per 
person, in a 24 hour period; or 
‘‘(II) has issued an alternate place 
of sale license to the retail location and 
has issued an alternate dispenser li-
cense to the person authorized to make 
the sale under subsections (i) and (j) of 
section 303, respectively; 
‘‘(ii) the person dispensing the con-
trolled substance described in paragraph (6) 
of schedule V follows the procedures set forth 
in this Act; and 
‘‘(iii) the person authorized under sec-
tion 303(i) dispensing the controlled sub-
stance described in paragraph (6) of sched-
ule V provides notification, in writing, of 
the intention to dispense such substance 
pursuant to a special exception under this 
subparagraph to each State and local law
251 
HR 2862 PP 
enforcement authority with jurisdiction to 
investigate crimes involving controlled sub-
stances at such location. 
‘‘(D) PRESCRIPTIONS.—The limit described 
in paragraph (2)(C) shall not apply to any 
quantity of such substance dispensed under a 
valid prescription. 
‘‘(4) REGULATIONS.— 
‘‘(A) RULES FOR LOGS.— 
‘‘(i) IN GENERAL.—The Attorney Gen-
eral shall promulgate rules and regula-
tions— 
‘‘(I) prescribing the content and 
format of the log required in para-
graph (2)(B)(ii); 
‘‘(II) establishing the manner in 
which the information in the log re-
quired in paragraph (2)(B)(ii) shall be 
reported to law enforcement authori-
ties; and 
‘‘(III) 
prohibiting 
accessing, 
using, or sharing the information in 
the log for any purpose other than to 
ensure compliance with this Act or to
252 
HR 2862 PP 
facilitate a product recall necessary to 
protect public health and safety. 
‘‘(ii) 
MISREPRESENTATION
WARN-
ING.—The rules and regulations under 
clause (i) shall require that the log explain 
the potential consequences of false state-
ments or misrepresentations, including re-
quiring that the following statement is 
prominently presented: ‘NOTE: PENALTY 
FOR MISREPRESENTATION – Any mis-
representation (by omission or concealment, 
or by misleading, false, or partial answers 
may result in prosecution pursuant to sec-
tion 1001 of title 18, United States Code, 
which makes it a criminal offense, punish-
able by a maximum of 5 years imprison-
ment, $10,000 fine, or both, knowingly and 
willfully to make a false statement or rep-
resentation to any Department or Agency of 
the United States as to any matter within 
the jurisdiction of any Department or Agen-
cy of the United States.’ 
‘‘(B) 
ALTERNATE
IDENTIFICATION.—The 
Attorney General shall promulgate rules and reg-
ulations authorizing the acceptance of an alter-
253 
HR 2862 PP 
nate form of identification under paragraph 
(2)(B)(i) to be used electronically. 
‘‘(5) GOOD FAITH PROTECTION.—A retailer who 
in good faith releases information maintained under 
this subsection for purposes of compliance with this 
Act to a law enforcement or regulatory authority es-
tablished pursuant to Federal or State law is immune 
from civil liability unless the release constitutes gross 
negligence or intentional, wanton, or willful mis-
conduct.’’. 
(c) ALTERNATE PLACE OF SALES AND DISPENSERS.— 
Section 303 of the Controlled Substances Act (21 U.S.C. 
823) is amended by adding at the end the following: 
‘‘(i) ALTERNATE PLACE OF SALES LICENSES.— 
‘‘(1) IN GENERAL.—The Attorney General shall 
register an applicant to dispense a controlled sub-
stance described in paragraph (6) of schedule V at a 
location other than a pharmacy if the Attorney Gen-
eral determines that such registration is consistent 
with the public interest. 
‘‘(2) CONSIDERATIONS.—In determining the pub-
lic interest, the Attorney General shall consider— 
‘‘(A) the applicant’s maintenance of effec-
tive controls against diversion of the controlled 
substance described in paragraph (6) of schedule
254 
HR 2862 PP 
V into other than legitimate channels equivalent 
to that of a pharmacy; 
‘‘(B) the applicant’s compliance with appli-
cable State and local law, including holding a 
valid license issued by an appropriate State au-
thority evidencing compliance with subpara-
graph (A); 
‘‘(C) the applicant’s prior conviction record 
under Federal and State laws; and 
‘‘(D) such other factors as may be relevant 
to and consistent with the public health and safe-
ty, including accessibility to rural consumers. 
‘‘(3) STATE LICENSES.—If an applicant under 
paragraph (1) does not have a valid State license as 
described in paragraph (2)(B), the Attorney General 
shall not register the applicant for a license under 
this subsection. 
‘‘(j) ALTERNATE DISPENSER LICENSES.— 
‘‘(1) IN GENERAL.—The Attorney General shall 
register an applicant, other than a practitioner, to 
dispense a controlled substance described in para-
graph (6) of schedule V at a location other than a 
pharmacy if the Attorney General determines that 
such registration is consistent with the public interest.
255 
HR 2862 PP 
‘‘(2) CONSIDERATIONS.—In determining the pub-
lic interest, the Attorney General shall consider— 
‘‘(A) the applicant’s compliance with appli-
cable State and local law, including holding a li-
cense issued by an appropriate State authority 
evidencing a degree of suitability to dispense the 
controlled substance described in paragraph (6) 
of schedule V equivalent to that of a practitioner; 
‘‘(B) the applicant’s prior conviction record 
under Federal and State laws; and 
‘‘(C) such other factors as may be relevant 
to and consistent with the public health and safe-
ty, including accessibility to rural consumers. 
‘‘(3) STATE LICENSES.—If an applicant under 
paragraph (1) does not have a valid State license as 
described in paragraph (2)(B), the Attorney General 
shall not register the applicant for a license under 
this subsection.’’. 
(d) THEFT
PREVENTION.—Notwithstanding para-
graph (6) of schedule V of section 202 of the Controlled Sub-
stances Act (21 U.S.C. 812), as added by subsection (a), 
persons registered with the Drug Enforcement Administra-
tion to manufacture or distribute controlled substances shall 
maintain adequate security and provide effective controls 
and procedures to guard against theft and diversion, but
256 
HR 2862 PP 
shall not otherwise be required to meet the meet the storage, 
reporting, recordkeeping, or physical security control re-
quirements (such as a cage or vault) for controlled sub-
stances in schedule V containing pseudoephedrine or ephed-
rine. 
(e) STATE PENALTIES AND PEDIATRIC PRODUCTS.— 
Nothing in this Act shall be construed to— 
(1) prevent a State or political subdivision of a 
State from adopting and enforcing penalties that are 
different from, in addition to, or otherwise not iden-
tical with, the penalties that apply under the Con-
trolled Substances Act (28 U.S.C. 801 et seq.); or 
(2) prevent a State or political subdivision of a 
State from permitting the sale of pediatric products 
containing pseudoephedrine or ephedrine, their salts 
or optical isomers, or salts of optical isomers where 
the pediatric product— 
(A) is primarily intended for administra-
tion, according to label instructions, to children 
under 12 years of age and either— 
(i) in solid dosage form, individual 
dosage units do not exceed 15 milligrams of 
ephedrine or pseudoephedrine; or 
(ii) in liquid form, recommended dos-
age units, according to label instructions, do
257 
HR 2862 PP 
not exceed 15 milligrams of ephedrine or 
pseudoephedrine per 5 milliliters of liquid 
product; or 
(B) is in liquid form— 
(i) primarily intended for administra-
tion to children under 2 years of age; 
(ii) the recommended dosage of which 
does not exceed 2 milliliters; and 
(iii) the total package content is not 
more than 1 fluid ounce. 
(f) EFFECTIVE DATES.— 
(1) ONLY ACTIVE INGREDIENT.—This section and 
the amendments made by this section shall take effect 
with regard to any substance in which ephedrine or 
pseudoephedrine is the only active ingredient 90 days 
after the date of enactment of this Act. 
(2) OTHER
PRODUCTS.—This section and the 
amendments made by this section shall take effect 
with regard to any substance other than a substance 
described in paragraph (1) on January 1, 2007. 
SEC. 711. EMPLOYER SCREENING OF EMPLOYEES WORKING 
WITH CONTROLLED SUBSTANCES. 
Part C of the Controlled Substances Act (21 U.S.C. 
821 et seq.) is amended by adding at the end the following:
258 
HR 2862 PP 
‘‘APPLICANTS AND EMPLOYEES 
‘‘SEC. 311. Persons registered with the Drug Enforce-
ment Administration to manufacture, deliver, distribute, or 
dispense controlled substances shall take reasonable steps to 
guard against hiring persons who may, as a result of their 
employment, have access to and become involved in the theft 
and diversion of controlled substances, including, notwith-
standing State law, asking applicants for employment 
whether they have been convicted of any crime involving 
or related to controlled substances.’’. 
Subtitle B—Education, Prevention, 
and Treatment 
SEC. 721. GRANTS FOR SERVICES FOR CHILDREN OF SUB-
STANCE ABUSERS. 
Section 519 of the Public Health Service Act (42 
U.S.C. 290bb–25) is amended— 
(1) in subsection (b), by inserting after para-
graph (8) the following: 
‘‘(9) Development of drug endangered children 
rapid response teams that will intervene on behalf of 
children exposed to methamphetamine as a result of 
residing or being present in a home-based clandestine 
drug laboratory.’’; and 
(2) in subsection (o)—
259 
HR 2862 PP 
(A) by striking ‘‘For the purpose’’ and in-
serting the following: 
‘‘(1) IN GENERAL.—For the purpose’’; and 
(B) by adding at the end the following: 
‘‘(2) DRUG ENDANGERED CHILDREN RAPID RE-
SPONSE TEAMS.—There are authorized to be appro-
priated $2,500,000 for each of the fiscal years 2006 
and 2007 to carry out the provisions of subsection 
(b)(9).’’. 
SEC. 722. LOCAL GRANTS FOR TREATMENT OF METH-
AMPHETAMINE ABUSE AND RELATED CONDI-
TIONS. 
Subpart 1 of part B of title V of the Public Health 
Service Act (42 U.S.C. 290bb et seq.) is amended— 
(1) by redesignating section 514 that relates to 
methamphetamine and appears after section 514A as 
section 514B; 
(2) in section 514B, as redesignated— 
(A) by amending subsection (a)(1) to read 
as follows: 
‘‘(1) GRANTS AUTHORIZED.—The Secretary may 
award grants to States, political subdivisions of 
States, American Indian Tribes, and private, non-
profit entities to provide treatment for methamphet-
amine abuse.’’;
260 
HR 2862 PP 
(B) by amending subsection (b) to read as 
follows: 
‘‘(b) PRIORITY FOR HIGH NEED STATES.—In award-
ing grants under subsection (a), the Secretary shall give 
priority to entities that will serve rural or urban areas ex-
periencing an increase in methamphetamine abuse in 
States with addiction rates in excess of the national rate.’’; 
and 
(C) in subsection (d)(1), by striking ‘‘2000’’ 
and all that follows and inserting ‘‘2005 and 
such sums as may be necessary for each of fiscal 
years 2006 through 2009’’; and 
(3) by inserting after section 514B, as redesig-
nated, the following: 
‘‘SEC. 514C. METHAMPHETAMINE RESEARCH, TRAINING, 
AND TECHNICAL ASSISTANCE CENTER. 
‘‘(a) PROGRAM AUTHORIZED.—The Secretary, acting 
through the Administrator, and in consultation with the 
Director of the National Institutes of Health, shall award 
grants to, or enter into contracts with, public or private, 
nonprofit entities to establish a research, training, and tech-
nical assistance center to carry out the activities described 
in subsection (d). 
‘‘(b) APPLICATION.—A public or private, nonprofit en-
tity seeking a grant or contract under subsection (a) shall
261 
HR 2862 PP 
submit an application to the Secretary at such time, in 
such manner, and containing such information as the Sec-
retary may require. 
‘‘(c) CONDITION.—In awarding grants or entering into 
contracts under subsection (a), the Secretary shall ensure 
that not less than 1 of the centers will focus on methamphet-
amine abuse in rural areas. 
‘‘(d) AUTHORIZED ACTIVITIES.—Each center estab-
lished under this section shall— 
‘‘(1) engage in research and evaluation of the ef-
fectiveness of treatment modalities for the treatment of 
methamphetamine abuse; 
‘‘(2) disseminate information to public and pri-
vate entities on effective treatments for methamphet-
amine abuse; 
‘‘(3) provide direct technical assistance to States, 
political subdivisions of States, and private entities 
on how to improve the treatment of methamphetamine 
abuse; and 
‘‘(4) provide training on the effects of meth-
amphetamine use and on effective ways of treating 
methamphetamine abuse to substance abuse treatment 
professionals and community leaders.
262 
HR 2862 PP 
‘‘(e) REPORTS.—Each grantee or contractor under this 
section shall annually submit a report to the Administrator 
that contains— 
‘‘(1) a description of the previous year’s activi-
ties of the center established under this section; 
‘‘(2) effective treatment modalities undertaken by 
the center; and 
‘‘(3) evidence to demonstrate that such treatment 
modalities were successful. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There are 
authorized to be appropriated to carry out this section 
$3,000,000 for fiscal year 2006 and such sums as may be 
necessary for each of fiscal years 2007 and 2008.’’. 
SEC. 723. METHAMPHETAMINE PRECURSOR MONITORING 
GRANTS. 
(a) GRANTS AUTHORIZED.—The Attorney General, 
acting through the Bureau of Justice Assistance, may 
award grants to States to establish methamphetamine pre-
cursor monitoring programs. 
(b) PURPOSE.—The purpose of the grant program es-
tablished under this section is to— 
(1) prevent the sale of methamphetamine precur-
sors, such as pseudoephedrine and ephedrine, to indi-
viduals in quantities so large that the only reasonable
263 
HR 2862 PP 
purpose of the purchase would be to manufacture 
methamphetamine; 
(2) educate businesses that legally sell meth-
amphetamine precursors of the need to balance the le-
gitimate need for lawful access to medication with the 
risk that those substances may be used to manufacture 
methamphetamine; and 
(3) recalibrate existing prescription drug moni-
toring programs designed to track the sale of con-
trolled 
substances 
to 
also 
track 
the 
sale 
of 
pseudoephedrine or ephedrine in any amount greater 
than 6 grams. 
(c) USE OF GRANT FUNDS.—Grant funds awarded to 
States under this section may be used to— 
(1) implement a methamphetamine precursor 
monitoring program, including hiring personnel and 
purchasing computer hardware and software designed 
to monitor methamphetamine precursor purchases; 
(2) expand existing methamphetamine precursor 
or prescription drug monitoring programs to accom-
plish the purposes described in subsection (b); 
(3) pay for training and technical assistance for 
law enforcement personnel and employees of busi-
nesses that lawfully sell substances, which may be 
used as methamphetamine precursors;
264 
HR 2862 PP 
(4) improve information sharing between adja-
cent States through enhanced connectivity; or 
(5) make grants to subdivisions of the State to 
implement methamphetamine precursor monitoring 
programs. 
(d) APPLICATION.—Any State seeking a grant under 
this section shall submit an application to the Attorney 
General at such time, in such manner, and containing such 
information as the Attorney General may require. 
(e) AUTHORIZATION OF APPROPRIATIONS.—There are 
authorized to be appropriated $5,000,000 for each of the 
fiscal years 2006 and 2007 to carry out the provisions of 
this section. 
SEC. 724. AUTHORIZATION OF APPROPRIATIONS RELATING 
TO COPS GRANTS. 
(a) IN GENERAL.—In addition to any other funds au-
thorized to be appropriated for fiscal year 2006 for grants 
under part Q of title I of the Omnibus Crime Control and 
Safe Streets Act of 1968 (42 U.S.C. 3796dd et seq.), com-
monly known as the COPS program, there are authorized 
to be appropriated $15,000,000 for such purpose to provide 
training to State and local prosecutors and law enforcement 
agents for the investigation and prosecution of methamphet-
amine offenses.
265 
HR 2862 PP 
(b) RURAL SET-ASIDE.—Of amounts made available 
under subsection (a), $3,000,000 shall be available only for 
prosecutors and law enforcement agents for rural commu-
nities. 
SEC. 725. EXPANSION OF METHAMPHETAMINE HOT SPOTS 
PROGRAM TO INCLUDE PERSONNEL AND 
EQUIPMENT FOR ENFORCEMENT, PROSECU-
TION, AND CLEANUP. 
Section 1701(d) of the Omnibus Crime Control and 
Safe Streets Act of 1968 (42 U.S.C. 3796dd(d)) is amend-
ed— 
(1) in paragraph (11) by striking ‘‘and’’ at the 
end; 
(2) in paragraph (12) by striking the period at 
the end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(13) hire personnel and purchase equipment to 
assist in the enforcement and prosecution of meth-
amphetamine offenses and the cleanup of meth-
amphetamine-affected areas.’’. 
SEC. 726. SPECIAL UNITED STATES ATTORNEYS’ PROGRAM. 
(a) IN GENERAL.—The Attorney General shall allocate 
any amounts appropriated pursuant to the authorization 
under subsection (c) for the hiring and training of special 
assistant United States attorneys.
266 
HR 2862 PP 
(b) USE OF FUNDS.—The funds allocated under sub-
section (a) shall be used to— 
(1) train local prosecutors in techniques used to 
prosecute methamphetamine cases, including the pres-
entation of evidence related to the manufacture of 
methamphetamine; 
(2) train local prosecutors in Federal and State 
laws involving methamphetamine manufacture or dis-
tribution; 
(3) cross-designate local prosecutors as special 
assistant United States attorneys; and 
(4) hire additional local prosecutors who— 
(A) with the approval of the United States 
attorney, shall be cross-designated to prosecute 
both Federal and State methamphetamine cases; 
(B) shall be assigned a caseload, whether in 
State court or Federal court, that gives the high-
est priority to cases in which— 
(i) charges related to methamphet-
amine manufacture or distribution are sub-
mitted by law enforcement for consider-
ation; and 
(ii) the defendant has been previously 
convicted of a crime related to methamphet-
amine manufacture or distribution.